Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients...
More...
iHav.net - Your Uncensored Offtopic Community
If this is your first visit, please click the Sign Up now button to begin the process of creating your account so you can begin posting on our forums! The Sign Up process will only take up about a minute of two of your time.
|
|
|
Results 1 to 1 of 1
-
10-22-2010, 01:00 PM #1Senior Member
- Join Date
- Mar 2008
- Posts
- 12,518
- Downloads
- 0
- Uploads
- 0
ARIKACE™ Demonstrates Sustained Benefit In Multiple Studies And Over Multiple Cycles
Reply With QuoteSimilar Threads
-
ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 06-19-2010, 12:03 PM -
ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 06-19-2010, 12:02 PM -
ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 06-19-2010, 12:01 PM -
ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 06-19-2010, 12:00 PM -
Phase 2 Trial Of LX4211 Demonstrates Significant And Rapid Improvements In Multiple P
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 01-23-2010, 01:03 PM
Bookmarks